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DLBCL, the most common lymphoma entity, is a potentially curable but heterogeneous disease. Most 
studies concerning therapy and prognostic factors have been performed on selected patient materials. It 
is important to identify immunohistochemical biomarkers which could add prognostic information to 
clinical factors. Recently, the combination of rituximab (R) and chemotherapy has resulted in improved 
survival, but still a proportion of patients fail to not reach sustained remission. Dysregulated apoptosis 
has been suggested to be involved in R-chemotherapy resistance. 
The aims were to retrospectively investigate i) administered therapy, survival and clinical prognostic 
factors in a non-selected, population-based cohort, and for those who had received chemotherapy with 
curative potential, investigate the prognostic role of ii) tumour infiltrating CD3+ lymphocytes, TIA-1+ 
and perforin+ cytotoxic T cells (CTLs) and FOXP3+ regulatory T cells (Tregs), and iii) the proliferation 
markers Ki-67 and cyclin A, in the context of anti-apoptotic bcl-2 and galectin-3 proteins and germinal 
centre B-cell like (GCB) vs non-GCB phenotype (using CD10, bcl-6 and MUM-1). Finally, the aim was 
to investigate the prognostic role of iv) anti-apoptotic (bcl-2, MCL1, p-AKT, bcl-xL) and pro-apoptotic 
(Bax, Bak) proteins in patients treated with R-chemotherapy.   
Out of 535 patients diagnosed between 1995 and 2000 in Western Health Care Region, only 62% 
accomplished chemotherapy with curative potential. The prognostic value of International Prognostic 
Index (IPI) was confirmed, but, surprisingly, also male sex predicted worse outcome. 
Immunohistochemical analysis on almost 200 patients showed that i) a small number of TIA-1+ CTLs 
predicted better outcome, independent of IPI and sex, but FOXP3+ Tregs expression was not prognostic, 
and ii) low Ki-67 expression, bcl-2+ and non-GCB phenotype predicted inferior survival, independent 
of clinical factors. The impact of Ki-67 was independent of bcl-2 and non-GCB/GCB, respectively. 
In 106 patients treated with R-chemotherapy between 2005 and 2007, high p-AKT expression predicted 
worse survival, independent of clinical factors and bcl-2 status, a novel finding. Moreover, bcl-2 
overexpression still predicted worse outcome. This suggests that p-AKT and bcl-2 overexpression could 
be indicators of R-chemotherapy resistance of prognostic importance. 
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